Song Wenhuan, Sun Peipei, Zhao Tongzhen, Zang Yunxue, Dong Pengpeng, Tang Qi, Chen Wenyu, Chen Wenyi, Wang Zhenqing, Zhang QinHeng, Wang Yinglin, Yin Chunhui, Yu Mingkun
Binzhou Medical College Affiliated Traditional Chinese Medicine Hospital, Binzhou, China.
Binzhou Medical University, Binzhou, China.
Discov Oncol. 2025 Apr 10;16(1):508. doi: 10.1007/s12672-025-02234-7.
Lung cancer remains the leading cause of cancer-related deaths worldwide, with increasing attention being given to novel therapeutic strategies that target the mechanisms underlying tumor growth and drug resistance. Among these, ferroptosis, a regulated cell death driven by iron-dependent lipid peroxidation, has become a key focus in cancer research. Despite extensive research, the exact role of ferroptosis in lung cancer progression and treatment remains unclear, especially regarding its interaction with immune cells and the tumor microenvironment.
To address these limitations, this study utilizes a comprehensive bibliometric analysis to explore the current landscape of ferroptosis research in lung cancer. We collected data from the Web of Science Core Collection, covering articles published between 2015 and 2025, and analyzed them using advanced tools such as VOSviewer and CiteSpace.
This study uses a comprehensive bibliometric analysis to uncover key trends and emerging areas related to lung cancer in ferroptosis research. Recently, the focus has shifted from basic mechanisms to clinical applications, particularly in developing GPX4-targeted therapies and combination treatments. With increasing international collaboration, the United States and China have become key players. Interdisciplinary research, especially on ferroptosis and the cancer-immune system, offers new insights into its role in the tumor microenvironment and immunotherapy. Ferroptosis shows excellent promise in overcoming drug resistance by regulating iron-dependent lipid peroxidation and enhancing treatment efficacy. Future research should focus on ferroptosis' clinical translation, particularly in personalized medicine and overcoming resistance, offering broad prospects for lung cancer treatment.
This paper provides valuable insights into the trends, key contributors, and emerging frontiers of ferroptosis research in lung cancer. It identifies important developments that can serve as a foundation for translating ferroptosis-based therapies into clinical practice, particularly to address drug resistance in lung cancer.
肺癌仍然是全球癌症相关死亡的主要原因，针对肿瘤生长和耐药机制的新型治疗策略越来越受到关注。其中，铁死亡是一种由铁依赖性脂质过氧化驱动的程序性细胞死亡，已成为癌症研究的关键焦点。尽管进行了广泛研究，但铁死亡在肺癌进展和治疗中的确切作用仍不清楚，尤其是其与免疫细胞和肿瘤微环境的相互作用。
为解决这些局限性，本研究利用全面的文献计量分析来探索肺癌中铁死亡研究的现状。我们从科学网核心合集收集数据，涵盖2015年至2025年发表的文章，并使用VOSviewer和CiteSpace等先进工具进行分析。
本研究通过全面的文献计量分析揭示了肺癌中铁死亡研究的关键趋势和新兴领域。最近，研究重点已从基本机制转向临床应用，特别是在开发靶向GPX4的疗法和联合治疗方面。随着国际合作的增加，美国和中国已成为关键参与者。跨学科研究，特别是关于铁死亡与癌症免疫系统的研究，为其在肿瘤微环境和免疫治疗中的作用提供了新见解。铁死亡在通过调节铁依赖性脂质过氧化和提高治疗效果来克服耐药性方面显示出巨大潜力。未来的研究应侧重于铁死亡的临床转化，特别是在个性化医疗和克服耐药性方面，为肺癌治疗提供广阔前景。
本文为肺癌中铁死亡研究的趋势、主要贡献者和新兴前沿提供了有价值的见解。它确定了重要进展，可作为将基于铁死亡的疗法转化为临床实践的基础，特别是用于解决肺癌中的耐药性问题。
